Tasisulam

Generic Name
Tasisulam
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C11H6BrCl2NO3S2
CAS Number
519055-62-0
Unique Ingredient Identifier
1YC4W9MSLJ
Background

Tasisulam has been used in trials studying the treatment and basic science of Melanoma, Lymphoma, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Safety Study in Participants With Advanced Solid Tumors

First Posted Date
2011-01-27
Last Posted Date
2019-01-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
234
Registration Number
NCT01284335
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yakima, Washington, United States

A Phase 1 Study in Patients With Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: LY573636
Drug: Pemetrexed
First Posted Date
2010-10-07
Last Posted Date
2019-03-15
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
39
Registration Number
NCT01215916
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Brunswick, New Jersey, United States

A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients

Phase 1
Terminated
Conditions
Advanced Cancer
Interventions
Drug: Tasisulam
Drug: Midazolam
First Posted Date
2010-09-27
Last Posted Date
2019-03-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
11
Registration Number
NCT01209832
Locations
🇫🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France

A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma

Phase 1
Terminated
Conditions
Lymphoma
Advanced Cancer
Interventions
Drug: Tolbutamide
Drug: Tasisulam
First Posted Date
2010-08-20
Last Posted Date
2018-10-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
4
Registration Number
NCT01185548
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Phase 2
Completed
Conditions
Metastatic Melanoma
Interventions
Drug: tasisulam
First Posted Date
2006-10-03
Last Posted Date
2018-06-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
130
Registration Number
NCT00383292
Locations
🇦🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy